VIR Q4 2024 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-26.3% YoY

Gross Profit

-$76M-617.5% margin

Operating Income

-$117M-946.7% margin

Net Income

-$105M-845.2% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

+419.9%

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$90M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$248M

Stockholders' Equity

$1.2B

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$17M	-26.3%
Gross Profit	-$76M	-$90M	+14.7%
Operating Income	-$117M	-$139M	+15.7%
Net Income	-$105M	-$116M	+9.8%

Revenue Segments

Collaboration Revenue

$8M81%

Grant

$1M11%

Contract Revenue

$865,0008%